Health ❯ Obesity

Weight Loss Treatments

GLP-1 Drugs Pharmaceuticals Medications GLP-1 Agonists Clinical Trials Drug Efficacy GLP-1 Receptor Agonists Prescription Drugs Drug Development GLP-1 Medications

3 ARTICLES

3w ago

Zealand Pharma Shares Tumble After Survodutide Phase III Shows High Dropouts

Detailed tolerability data have prompted investor concern because gastrointestinal side effects drove unusually high discontinuation rates that could limit the drug’s market uptake.

4 ARTICLES

last mo.

Generic Semaglutide Hits Canadian Pharmacy Shelves

8 ARTICLES

3mo ago

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

4 ARTICLES

4mo ago

BMJ Study Links GLP-1 Drugs to Lower Risk of Problematic Substance Use

3 ARTICLES

5mo ago

Eli Lilly Chooses Pennsylvania for $3.5 Billion Plant to Produce Weight-Loss Injectables

9 ARTICLES

5mo ago

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

9 ARTICLES

5mo ago

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound

4 ARTICLES

6mo ago

Brazil Expands Use of Mounjaro: Dentists Cleared to Prescribe as Vilhena Rolls Out Free Treatment

9 ARTICLES

7mo ago

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

11 ARTICLES

7mo ago

White House Strikes Deals With Lilly and Novo to Cut GLP-1 Prices, Widen Medicare Access

5 ARTICLES

9mo ago

Novo Nordisk Survey Finds Wegovy Users Report Sharp Drop in ‘Food Noise’

8 ARTICLES

10mo ago

Semaglutide Curbs Cocaine Use and Relapse-Seeking in Rats, Peer-Reviewed Study Finds

9 ARTICLES

10mo ago

UK and Eli Lilly Unveil £85m Pilot for Pharmacy and Digital Delivery of Weight-Loss Injections

5 ARTICLES

11mo ago

Guidelines Tie Diet and Exercise to GLP-1 Drug Success as India Launches Treatments

10 ARTICLES

last yr.

NHS Weight-Loss Jab Prescriptions Near Three Million as Experts Raise Lifelong Use Concerns

31 ARTICLES

last yr.

UK Approves Wegovy for Reducing Heart Risks in Overweight Patients

Weight Loss Treatments

Zealand Pharma Shares Tumble After Survodutide Phase III Shows High Dropouts

Generic Semaglutide Hits Canadian Pharmacy Shelves

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

BMJ Study Links GLP-1 Drugs to Lower Risk of Problematic Substance Use

Eli Lilly Chooses Pennsylvania for $3.5 Billion Plant to Produce Weight-Loss Injectables

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound

Brazil Expands Use of Mounjaro: Dentists Cleared to Prescribe as Vilhena Rolls Out Free Treatment

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

White House Strikes Deals With Lilly and Novo to Cut GLP-1 Prices, Widen Medicare Access

Never miss stories about

Weight Loss Treatments

Novo Nordisk Survey Finds Wegovy Users Report Sharp Drop in ‘Food Noise’

Semaglutide Curbs Cocaine Use and Relapse-Seeking in Rats, Peer-Reviewed Study Finds

UK and Eli Lilly Unveil £85m Pilot for Pharmacy and Digital Delivery of Weight-Loss Injections

Guidelines Tie Diet and Exercise to GLP-1 Drug Success as India Launches Treatments

NHS Weight-Loss Jab Prescriptions Near Three Million as Experts Raise Lifelong Use Concerns

Novo Nordisk CEO Steps Down Following Share Price Collapse

Novo Nordisk Faces Investor Turmoil as Wegovy Sales and Market Share Decline

Novo Nordisk Acquires Chinese Obesity Drug After CagriSema Trial Disappointment

Study Highlights Benefits and Risks of Popular Weight-Loss Drugs

UK Approves Wegovy for Reducing Heart Risks in Overweight Patients

Never miss stories about

Weight Loss Treatments